Hyperprogression after one dose of nivolumab in sinonasal cancer: A case report

Abstract

In head and neck squamous cell carcinoma, immune checkpoint inhibitors (ICI) lead to improved outcomes. There has been reports of accelerated disease progression, or hyperprogression, after ICI initiation. We present a case of hyperprogression after one dose of nivolumab in maxillary sinus squamous cell carcinoma. The patient had complete vision loss due to disease progression into the orbit, as well as intracranial invasion, lytic metastases, and new widespread distal metastases. Hyperprogression can occur after the first dose of immunotherapy. Absent biomarkers regarding individual risk of hyperprogression, caution should be exercised in using ICI in sinonasal cancers with orbital abutting disease. Laryngoscope, 130:907–910, 2020

Regression of advanced maxillary sinus cancer with orbital invasion by combined chemotherapy and immunotherapy: A one‑year follow‑up case report

“…Immune checkpoint blockade has emerged as a promising treatment option. Numerous anti-PD-1 and anti-PD-L1 antibodies are under investigation, and two of them (nivolumab and pembrolizumab) were approved by the Food and Drug Administration (FDA) in 2016 for sinonasal cancers (7). PD-1 and its ligands (PD-L1 and PD-L2) are mainly involved in the modulation of T-cell activity.…”